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CASE REPORT
The concurrent occurrence of autoimmune hepa-
titis (AIH) and myasthenia gravis (MG) has rarely been 
reported with thymoma. We describe what we believe is the 
first reported case of a newly diagnosed, unresectable thy-
moma with acute-onset transaminitis and myasthenic crisis 
that responded to chemotherapy after plasmapheresis.
A 42-year-old white woman with a World Health 
Organization B2/B3, stage IVA thymoma presented with 
fatigue, dyspnea, and orthopnea. Laboratory workup 
showed transaminitis (aspartate transaminase 377 U/liter, 
upper limit of normal [ULN] 34 U/liter; alanine aminotrans-
ferase 357 U/liter, ULN 41 U/liter; elevated creatine kinase, 
1462 U/liter, ULN 252 U/liter; and lactate dehydrogenase 
947 U/liter, ULN 226 U/liter), no serological evidence of 
hepatitis A, B, or C infection, and absence of anti–smooth 
muscle and antinuclear antibodies. Hepatic ultrasound 
showed no metastases and patent veins. The patient’s symp-
toms continued to worsen, and approximately 4 weeks after 
diagnosis of thymoma, she developed dysarthria, dyspha-
gia, and mental status changes culminating in unrespon-
siveness, for which intubation and mechanical ventilation 
were required. Troponin I was elevated at 0.165 ng/ml (ULN 
0.045 ng/ml) but a transthoracic echocardiogram was unre-
markable. A diagnosis of thymoma-associated myasthenic 
crisis, acute AIH, myositis, and myocarditis was made, and 
plasmapheresis initiated immediately because of the life-
threatening nature of myasthenic crisis. Serum acetylcho-
line receptor binding antibody levels were elevated at 4.91 
nmol/liter (ULN 0.02 nmol/liter), thus, confirming MG. 
Plasmapheresis resulted in rapid clinical improvement and 
near normalization of biochemical parameters but ventilator 
dependence continued. Pyridostigmine at a dose of 60 mg 
every 8 hours was started 4 days after completion of plas-
mapheresis to provide symptomatic relief from ptosis and 
residual myasthenic symptoms. Steroids were not used at 
any stage during hospitalization or for maintenance therapy, 
except as part of routine antiemetic prophylaxis before and 
during administration of chemotherapy. For this purpose, 
dexamethasone was administered intravenously at a dose of 
12 mg once, 1 hour before initiation of chemotherapy, fol-
lowed by 4 mg every 12 hours for a total of 6 doses, start-
ing the following day. Chemotherapy (cisplatin 50 mg/m2, 
doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2, 
all administered on day 1 and repeated every 21 days) was 
started 8 days after completion of plasmapheresis, and the 
patient came off ventilatory support within 48 hours. Levels 
of liver enzymes, creatine kinase, and lactate dehydroge-
nase at key time points are depicted in Figure 1. A computed 
tomography scan confirmed tumor shrinkage after one cycle 
of chemotherapy (Fig. 2). The patient received two cycles 
of chemotherapy during her hospitalization, after which 
she was discharged. She went on to receive an additional 
four cycles of chemotherapy as an outpatient, and achieved 
a very good partial response, with no recurrence of myas-
thenic symptoms.
Thymomas are rare tumors with an incidence of 0.13 
cases per 100,000 person-years.1 Autoimmune disorders 
occur with thymoma, the most common of which is MG.2 
AIH has also been reported.3 Up to 7% of patients with 
thymoma and MG have other paraneoplastic conditions.4 
Although thymectomy is the preferred treatment modal-
ity, not all patients are surgical candidates. Steroid therapy 
can control AIH but can initially worsen MG and precipi-
tate a myasthenic crisis whereas plasmapheresis can result 
in significant, although temporary improvement. This case 
highlights the need to recognize the benefit of rapid initia-
tion of chemotherapy after plasmapheresis in patients with 
unresectable thymoma to gain durable control of associated 
autoimmune disorders.
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FIGURE 2.  Computed tomography scan 
demonstrating an anterior mediastinal mass at 
baseline (A) and tumor shrinkage 3 weeks after 
initiation of chemotherapy (B).
FIGURE 1.  Changes in laboratory 
parameters at key time points. AST, 
aspartate aminotransferase; ALT, ala-
nine aminotransferase; CK, creatine 
kinase; LDH, lactate dehydrogenase; 
NIH, National Institutes of Health.
